Call for Abstract

7th International Conference and Exhibition on Cell and Gene Therapy, will be organized around the theme “Exploring the novel research and innovations in Cell & gene therapy”

Cell Therapy 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Cell Therapy 2018

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Cell Therapies
  • Track 1-2Somatic Cell Nuclear Transfer (SCNT)
  • Track 1-3Embryonic Stem Cells (ES cells)
  • Track 1-4Hematopoietic Stem Cells Transplant(HSCT)
  • Track 1-5Gene Therapy
  • Track 1-6Antisense Technology
  • Track 2-1Cell Culture
  • Track 2-2Immortalized Cell Lines and its Types
  • Track 2-3Human Cell Lines
  • Track 2-4Plant Cell Lines
  • Track 2-5Primate Cell Lines
  • Track 2-6Cancer Cell Line
  • Track 3-1Viral Vector in Gene Therapy
  • Track 3-2Retroviral and Other Viral Vector
  • Track 3-3Non -Viral Vectors in Gene Therapy
  • Track 3-4Calcium Phosphate Transfection
  • Track 3-5Electroporation
  • Track 3-6Targeted Vector Systems
  • Track 3-7Transductional Targeting
  • Track 3-8Fusion Protein Targeting
  • Track 3-9Targeting Cell Surface Molecules
  • Track 4-1Orthopedic Repair
  • Track 4-2Neurological Disorder
  • Track 4-3Blindness Vision Impairment
  • Track 4-4Wound Healing
  • Track 4-5Cancer
  • Track 4-6HIV
  • Track 4-7Cardiovascular Disorder
  • Track 4-8Inherited Muscular Disorder
  • Track 5-1Immunotherapy
  • Track 5-2Biomaterial Mediated Gene Therapy
  • Track 5-3Extracellular Matrix in Reconstructive Surgery
  • Track 5-4Endothelial Progenitor Cells
  • Track 5-5Tissue Remodelling
  • Track 6-1Molecular Bridge
  • Track 6-2Neuroepigenetics
  • Track 6-3Histone Post-Translational Modification
  • Track 6-4DNA Methylation
  • Track 6-5Prion Based Epigenetic Inheritance
  • Track 6-6Cellular Storage Information
  • Track 7-1Evidence on Medicine
  • Track 7-2Ethical Issues
  • Track 7-3Clinical Risks
  • Track 7-4Preclinical Issues
  • Track 7-5Regulatory and Safety Aspects
  • Track 7-6Chemistry,Manufacturing and Controls (CMC )Information
  • Track 8-1Plant Stem Cells as Anti Oxidant
  • Track 8-2Anti Photoaging Effect
  • Track 8-3Strategies for Engineered Scenescence
  • Track 8-4Hematopoietic Stem Cell Aging
  • Track 8-5Hair Follicle Stem Cell Aging
  • Track 9-1Biomarkers
  • Track 9-2Metabolic Imaging Technology
  • Track 9-3Computational Modelling
  • Track 9-4Bio Informatics
  • Track 9-5 Quantitative Pharmacology
  • Track 9-6Gene Therapy for Bone Engineering
  • Track 9-7Talen Technology
  • Track 10-1Nano Technology in Gene Therapy
  • Track 10-2Non Viral Vector
  • Track 10-3Immune System Modulation
  • Track 10-4DNA Nanotechnology
  • Track 10-5Biodegradable Nanoparticles
  • Track 10-6Nano Dimensional Artificial Antigen Presenting Cells (aAPCs)
  • Track 11-1Genetic Engineering
  • Track 11-2Zinc Finger Nucleases 
  • Track 11-3Crispr Technology
  • Track 11-4Talen Technology
  • Track 12-1Homing Endonucleases or Meganucleases
  • Track 12-2Functional Biomaterial
  • Track 12-3Acquisition of Novel Biological or Molecular Diversity. 
  • Track 12-4DNA Synthesis
  • Track 12-5DNA Shuffling
  • Track 12-6Directed Design
  • Track 13-1Bioprospecting
  • Track 13-2Genotype-Specific Medicine
  • Track 13-3Phenotype-Specific Medicine
  • Track 13-4Epidermal Growth Factor Receptor (EGFR)
  • Track 13-5EGFR Inhibitor
  • Track 13-6Single Nucleotide Polymorphisms
  • Track 14-1Systems Biology
  • Track 14-2Computational Biology and Bioinformatics
  • Track 14-3DNA Computer
  • Track 14-4Annual Growth Rate
  • Track 14-5Commercial Collaboration
  • Track 15-1Cell Therapy in Market
  • Track 15-2Allogenic Technology in Market
  • Track 15-3Cell and Gene Therapy Companies
  • Track 15-4Alliance Companies
  • Track 15-5Blooming Era of Gene Therapy